Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysregulated inflammation. Therapeutic innovations such as nebulized antimicrobial therapy targeting specific pathogens have resulted in improvements in quality of life and life expectancy. Aztreonam lysine for inhalation (AZLI) solution was initially app...
Alternative Titles
Full title
Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1c5ccf8b42d04eb1ab0176cd0283460a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1c5ccf8b42d04eb1ab0176cd0283460a
Other Identifiers
ISSN
1179-5484
E-ISSN
1179-5484
DOI
10.1177/1179548419842822
